Overview

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Status:
Recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Phase:

Phase 3

Details

Lead Sponsor:

BeiGene

Treatments:

Bendamustine Hydrochloride
Rituximab
Zanubrutinib